Hormonal
Bariatric surgery, particularly malabsorptive and hybrid procedures like Roux-en-Y gastric bypass, can completely reverse established type 2 diabetes mellitus in a large percentage of patients, often within days of surgery, independent of significant weight loss, likely due to hormonal changes.
If you have type 2 diabetes and undergo bariatric surgery, there is a high chance your diabetes may go into remission, often within days of the procedure, even before you lose significant weight. This is due to hormonal changes in your gut that improve how your body handles insulin. However, long-term remission depends on maintaining your weight loss and following up with your healthcare team.
The most clinically relevant impact of surgically induced... compared with medically induced weight loss on diabetes mellitus is the ability of the former to completely reverse established diabetes mellitus in a large percentage of subjects... Improvements in insulin sensitivity have also been documented within days of bariatric surgery and before any observed weight loss.
Why this rating
Based on long-term controlled studies and meta-analyses, though mechanisms are still debated.
Source
Bariatric Surgery and Cardiovascular Risk Factors
Paul Poirier et al. · Circulation · 2011
DOI 10.1161/cir.0b013e3182149099
More from this paper
- Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) significantly reduces excess body weight (average 50-70% excess weight loss) and durably improves or resolves severe obesity-related comorbidities including type 2 diabetes, hypertension, and dyslipidemia, leading to prolonged survival compared to non-surgical management.Good
- Bariatric surgery significantly improves lipid profiles, particularly by reducing triglycerides and increasing HDL cholesterol, with Roux-en-Y gastric bypass showing greater effects on triglycerides than restrictive procedures.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →